Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19201191 | 1.00 | FFAR2 (0.32) | FFAR2MMP1 | |
| SCHEMBL27376558 | 0.85 | ELANE (0.33) | MMP1 | |
| SCHEMBL15033256 | 0.84 | MMP1 (0.38) | FFAR2MMP1 | |
| SCHEMBL29878045 | 0.84 | MMP1 (0.38) | FFAR2MMP1 | |
| SCHEMBL22421642 | 0.84 | MMP1 (0.38) | FFAR2MMP1 | |
| SCHEMBL24337164 | 0.84 | MMP1 (0.38) | FFAR2MMP1 | |
| SCHEMBL19401641 | 0.84 | FFAR2 (0.36) | FFAR2MMP1 | |
| SCHEMBL14511336 | 0.84 | FFAR2 (0.36) | FFAR2MMP1 | |
| SCHEMBL13260893 | 0.84 | FFAR2 (0.36) | FFAR2MMP1 | |
| SCHEMBL24200030 | 0.83 | HIF1A (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2558127-B1 | TARGETED PYRROLOBENZODIAZEPINE CONJUGATES | SEAGEN INC (US) | 2022-01-19 | — | — | EP | disclosed |
| US-10751346-B2 | Pyrrolobenzodiazepine—anti-PSMA antibody conjugates | MEDIMMUNE LIMITED (GB) | 2020-08-25 | — | — | US | disclosed |
| US-20180127505-A1 | HUMANIZED ANTI-AXL ANTIBODIES AND THEIR CONJUGATES | ADC THERAPEUTICS SA (CH) | 2018-05-10 | — | — | US | disclosed |
| WO-2017129652-A1 | PYRROLOBENZODIAZEPINES | MEDIMMUNE LIMITED (GB) | 2017-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180127505-A1 | HUMANIZED ANTI-AXL ANTIBODIES AND THEIR CONJUGATES | AXL, TYRO3, FLT3 | FFAR2 2235/4885MMP1 4816/4885 |
| US-10751346-B2 | Pyrrolobenzodiazepine—anti-PSMA antibody conjugates | PSMA2, PSMA7, FOLH1 | FFAR2 4101/4885MMP1 3875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.